VEGFR2/KDR/Flk-1 Antibody

Product Discontinued

VEGFR2/KDR/Flk-1 Antibody Summary

• Immunogen: A synthetic peptide made to a C-terminal region of the mouse VEGF Receptor 2 protein (between residues 1300-1367). [Swiss-Prot# P35918]
• Localization: Type I membrane protein
• Marker: Endothelial Cell Marker
• Specificity: This has only been shown to recognize the native form (180-190 kDa protein) of VEGFR-2, known as Flk-1/KDR/VEGFR 2 (Vascular Endothelial Growth Factor Receptor 2), though it was raised against the precursor form.
• Predicted Species: Mouse (100%). Backed by our 100% Guarantee.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: KDR
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry
  • Immunocytochemistry/ Immunofluorescence 1:10
  • Western Blot 1 ug/ml
• Application Notes: This VEGF Receptor 2 antibody is useful for Immunocytochemistry/Immunofluorescence and Western blot, where a doublet is seen at ~150 kDa with CSF-1R/VEGFR2 chimera transfected lysates representing VEGFR-2. A non-specific band is also seen at ~85 kDa. In ICC/IF punctate membrane staining was observed in Hela cells. Use in FLOW cytometry reported in scientific literature (PMID 27832737).
• Theoretical MW: 150 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Reactivity Notes

Human. Predicted to react with mouse based on 100% sequence homology. Immunogen sequence has 79% homology to rat. Hamster reactivity reported in scientific literature (PMID: 23763710). Rat reactivity reported in scientific literature (PMID: 27832737).

Packaging, Storage & Formulations

• Storage: Store at 4C. Do not freeze.
• Buffer: Tris-Citrate/Phosphate (pH 7.0 - 8.0)
• Preservative: 0.1% Sodium Azide
• Concentration: 1 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for VEGFR2/KDR/Flk-1 Antibody

• CD309 antigen
• CD309
• EC 2.7.10
• EC 2.7.10.1
• Fetal liver kinase 1
• fetal liver kinase-1
• Flk1
• Flk-1
• FLK1tyrosine kinase growth factor receptor
• KDR
• kinase insert domain receptor (a type III receptor tyrosine kinase)
• Kinase insert domain receptor
• KRD1
• Ly73
• Protein-tyrosine kinase receptor flk-1
• soluble VEGFR2
• vascular endothelial growth factor receptor 2
• VEGF R2
• VEGFR
• VEGFR2
• VEGFR-2

Background

VEGFs such as VEGFA, VEGFC, VEGFD etc. activate RTKs namely VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4), that regulates angiogenic as well as lymphangiogenic transduction signals. VEGF Receptor 2 (VEGFR2) is the most prominent cell-surface receptor for VEGF ligands and binding of VEGFs to isoform 1 leads to multiple signaling cascades activation. PLCG1 activation results in production of signaling molecules (diacylglycerol, inositol 1,4,5-trisphosphate etc) and PKC activation. VEGFR2 is involved in the activation of MAPK1/ERK2, MAPK3/ERK1, and MAPK as well as AKT signaling pathways. It facilitates phosphorylation of PIK3R1 (regulatory subunit of PI3K), cytoskeletal actin reorganization and PTK2/FAK1 activation. VEGFR2 is essential for VEGFA-mediated induction of NOS2/NOS3, leading to the production of NO by endothelial cells and is involved in phosphorylation of FYN, NCK1, NOS3, PIK3R1 and SRC. Isoforms -2 and -3 function as decoy receptors for VEGFs, and isoform -2 plays as negative regulator of VEGFA/VEGFC-mediated lymphangiogenesis by limiting free VEGFA and/or VEGFC levels alongwith preventing their binding to VEGFR3. Versatile signaling effects by VEGFR2 leads to its regulatory role in processes such as angiogenesis, vascular development, vascular permeability, embryonic hematopoiesis, and promotes proliferation, survival, migration and differentiation of endothelial cells alongwith facilitating reorganization of the actin cytoskeleton.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for VEGFR2/KDR/Flk-1 Antibody (NB100-2382)(5)

Publications using NB100-2382

• Roan, J N, Cheng, H N Et al. Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing. J Surg Res 2017-02-01 [PMID: 27993221] (IF/IHC, Mouse)
• Zhou J, Rogers J, Lee S et al. Oral mucosa harbors a high frequency of endothelial cells - a novel postnatal cell source for angiogenic regeneration. Stem Cells Dev. 2016-11-10 [PMID: 27832737] (FLOW, Rat)
  
  Details:
  This citation used the DyLight 488 version of this antibody.
• Lim UM, Yap MG, Lim YP et al. Identification of Autocrine Growth Factors Secreted by CHO Cells for Applications in Single-Cell Cloning Media. J Proteome Res 2013-07-05 [PMID: 23763710] (WB, Hamster)
• Roan JN, Fang SY, Chang SW et al. Rosuvastatin improves vascular function of arteriovenous fistula in a diabetic rat model. J Vasc Surg 2012-06-22 [PMID: 22727844] (FLOW, Rat)
  
  Details:
  Using the DyLight 488 conjugated version of NB100-2382, catalog number NB100-2382G.
• Hu-Lowe DD et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res;14(22):7272-83. 2008-11-15 [PMID: 19010843]

FAQs for VEGFR2/KDR/Flk-1 Antibody (NB100-2382). (Showing 1 - 1 of 1 FAQs).

1. Can provide this VEGF Receptor 2 antibody that is conjugated to DyLight 488?
   • NB100-2382G is conjugated to DyLight 488. NB100-2382 is unconjugated.

Bioinformatics

• Gene Symbol: KDR